secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2025-07-02T23:59:59+00:00
Accession:  0001140361-25-024413
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio monetizes EU acoramidis royalties for $300M cash; caps future payments
--------------------------------------------------------------------------------

- Eidos sold right to receive certain royalties on acoramidis net sales in EU and EPO states to ARS and LSI Financing Fund.
- Purchase price of $300M paid in full at closing on June 27, 2025.
- Purchaser's annual cap equals 60% of Bayer royalties on first $500M of net sales; hard cap at 145% of purchase price.
- Company granted security interest in assets related to purchased royalty payment; change of control triggers option to assume or pay adjusted amount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/0001140361-25-024413-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000114036125024413/ef20051467_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-024413

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer